To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Inclusion Criteria:

• Age ≥22 years

• Willing to enter a medication/lifestyle stabilization period during the screeningperiod, which means maintaining those stable medication, eating, and exercise habitsfor the duration of the study

• Subjects should be on stable background Lipid Modifying Therapy (LMT) to manageASCVD for a minimum of 4 weeks prior to first qualifying TG

Exclusion Criteria:

• Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or humanimmunodeficiency virus (HIV)

• Uncontrolled or newly diagnosed (≤3 months since diagnosis) Type 2 diabetes mellitusas determined by the Principal Investigator. Subjects must have HbA1c level ≤9.5% atScreening. Medications for glucose management must be stable for at least 4 weeksprior to Screening

• Type 1 diabetes mellitus

• A history of symptomatic gallstone disease, gallstone pancreatitis (unless treatedwith cholecystectomy), or any other ongoing symptomatic biliary disease

• Acute pancreatitis within 6 months prior to Screening

• Subjects with chronic pancreatitis

• Known or suspected familial chylomicronemia syndrome (FCS) (Type 1hyperlipoproteinemia)

Other inclusion and exclusion criteria may apply.